Wed, December 11, 2024
Tue, December 10, 2024
[ Tue, Dec 10th 2024 ] - The New Yorker
The Dawn of the Bionic Man
[ Tue, Dec 10th 2024 ] - Mercury News
California News
[ Tue, Dec 10th 2024 ] - ABC News
Entertainment News
Mon, December 9, 2024
[ Mon, Dec 09th 2024 ] - BBC
Beds, Herts & Bucks
[ Mon, Dec 09th 2024 ] - Uproxx
The Best TV Shows Of 2024
[ Mon, Dec 09th 2024 ] - Paste
The 25 Best PC Games of 2024
[ Mon, Dec 09th 2024 ] - CNET
Top News Stories
Sun, December 8, 2024
Sat, December 7, 2024
[ Sat, Dec 07th 2024 ] - Newsweek
Russia-Ukraine War
[ Sat, Dec 07th 2024 ] - imdb.com
Canada's 30 Funniest TV Shows
[ Sat, Dec 07th 2024 ] - Daily Mail
UK Celebrity News
[ Sat, Dec 07th 2024 ] - Food Safety News
Food Safety News
Fri, December 6, 2024
[ Fri, Dec 06th 2024 ] - Graphic
Latest Ghana News Headlines Today
[ Fri, Dec 06th 2024 ] - The Columbian
Clark County News
[ Fri, Dec 06th 2024 ] - who13
Cyclones react to 10 wins
[ Fri, Dec 06th 2024 ] - TravelPulse
Hotels and Resorts News
[ Fri, Dec 06th 2024 ] - Business Standard
Share Market Today
[ Fri, Dec 06th 2024 ] - Reuters
Aerospace & Defense
Thu, December 5, 2024
[ Thu, Dec 05th 2024 ] - Interest
All news stories
[ Thu, Dec 05th 2024 ] - Stereogum
When Comedians Make Serious Music
[ Thu, Dec 05th 2024 ] - Paste
The 30 Best TV Shows of 2024
[ Thu, Dec 05th 2024 ] - Phil Bruner
Featured News Stories
[ Thu, Dec 05th 2024 ] - Phil Bruner
Swattie Survival Guide
Wed, December 4, 2024
[ Wed, Dec 04th 2024 ] - Phil Bruner
California News
[ Wed, Dec 04th 2024 ] - Phil Bruner
President Joe Biden
Tue, December 3, 2024
[ Tue, Dec 03rd 2024 ] - Phil Bruner
The 40 Best Games of 2024
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Boku No Roblox Codes
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Yonhap News Agency
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Beds, Herts & Bucks
[ Tue, Dec 03rd 2024 ] - Phil Bruner
Transfer news and rumors
Mon, December 2, 2024
[ Mon, Dec 02nd 2024 ] - Phil Bruner
Watch Samaa News Live
[ Mon, Dec 02nd 2024 ] - Phil Bruner
UK Celebrity News
[ Mon, Dec 02nd 2024 ] - Phil Bruner
The 100 Best Albums of 2024
[ Mon, Dec 02nd 2024 ] - Phil Bruner
From the Newspaper
[ Mon, Dec 02nd 2024 ] - Phil Bruner
South Australia
[ Mon, Dec 02nd 2024 ] - Phil Bruner
Whanganui Chronicle
Sun, December 1, 2024
[ Sun, Dec 01st 2024 ] - Phil Bruner
Wildlife Oddities of the Week
Sat, November 30, 2024
Fri, November 29, 2024
[ Fri, Nov 29th 2024 ] - Phil Bruner
Hotels and Resorts News
[ Fri, Nov 29th 2024 ] - Phil Bruner
The Best Jokes of 2024
Thu, November 28, 2024
[ Thu, Nov 28th 2024 ] - Phil Bruner
Climate and Environment
[ Thu, Nov 28th 2024 ] - Phil Bruner
December 2024 Issue
Wed, November 27, 2024
[ Wed, Nov 27th 2024 ] - Phil Bruner
Decoding Gen Z's content diet
Tue, November 26, 2024
[ Tue, Nov 26th 2024 ] - Phil Bruner
Illustrated Humor in the News
[ Tue, Nov 26th 2024 ] - Phil Bruner
World News
[ Tue, Nov 26th 2024 ] - Phil Bruner
Alexandra Petri
Mon, November 25, 2024
[ Mon, Nov 25th 2024 ] - Phil Bruner
Legal IT's Leading News Source
[ Mon, Nov 25th 2024 ] - Phil Bruner
All Kent news
Sun, November 24, 2024
Mon, December 15, 2008
[ Mon, Dec 15th 2008 ] - Market Wire
fasdfasddva s gfg h

Advanced Cell Technologya?s Robust Cell Reprogramming/Transdifferentiation Platform Well Positioned To Capitalize on Emerging T


//health-fitness.news-articles.net/content/2010/ .. well-positioned-to-capitalize-on-emerging-t.html
Published in Health and Fitness on Monday, August 30th 2010 at 7:20 GMT by Market Wire   Print publication without navigation


MARLBOROUGH, Mass.--([ BUSINESS WIRE ])--Advanced Cell Technology, Inc. aACTa ([ OTCBB:ACTC ]) provides an update today on its plans to utilize its transdifferentiation platform to enhance regenerative medicine. Transdifferentiation involves reprogramming one type of adult cell, such as skin, into an altogether different type of cell, such as muscle or insulin-producing cells, without having to generate stem cells. This month scientists successfully turned ordinary fibroblasts into beating heart cells (Cell 142:375, 2010), providing new evidence that transdifferentiation will play an important role in the field of regenerative medicine. For over a decade ACT has actively continued to develop and innovate in the field of induced transdifferentiation, supported by robust intellectual property and has made significant progress discovering proprietary protocols and factors for inducing reprogramming of somatic cells with defined factors.

"Our field has evolved from considering cell differentiation as an irreversible event to slowly accepting that cell fate is responsive to manipulation even late in differentiation"

aOur field has evolved from considering cell differentiation as an irreversible event to slowly accepting that cell fate is responsive to manipulation even late in differentiation,a said Robert Lanza, M.D., Chief Scientific Officer at ACT. aAlthough there is a rich history to transdifferentiation, this research was pushed into the background with the advent of iPS cells. Only now is the regenerative medicine industry realizing its therapeutic appeal, and that some of the same techniques used for generating iPS cells can be used to directly reprogram one cell type into another. Even as researchers rush to implement the latest in stem-cell and iPS technologies, there is still a desire to manipulate cell identity without the need to begin with stem cells. Although transdifferentiation wona�t replace the need for stem cells, it offers another strategy which, like iPS cells, can be used to develop cell products for use in patients when those sources of cells may be safer or better tolerated."

ACTa�s efforts in the field of transdifferentiation date back to the late 1990a�s. In fact, the Company was awarded a seven-figure grant from the National Institute of Standards and Technology (NIST) to identify agents and conditions that predispose, through non-genetic modification, target cells such as fibroblasts to be more amenable to reprogramming factors. These proprietary processes may be particularly significant where the reprogramming factor would be delivered as an extracellular agent rather than through a recombinant expression vector, and consequently removes safety issues otherwise arising from genetically modifying cells as described in the recent transdifferentiation papers by Vierbuchen et al (Nature 463, 1035, 2010) and Leda et al (Cell, 142, 375, 2010) . The Company believes its proprietary technology is a necessary step to a predictable and safe process for the practical reprogramming of cells in a clinical product setting.

aOne of the fruits of ACTa�s early research efforts,a said William M. Caldwell IV, the Companya�s Chairman and CEO acomes in the form of a robust intellectual property estate generated by the company. We have patent filings with priority dates going back a decade or more, and are positioned to control central factors involved in inducing heart cell formation, including factors described in recent publications. The company has also been diligently protecting its IP relating to novel protocols and agents for predisposing differentiated cells to transdifferentiation. We have a very strong IP position in place through pending and issued patent filings, including a recently-issued broad patent for enhancing the generation of nerve cells from fibroblasts through transdifferentiation. We consider this a requirement to practical and safe use of transdifferentiation in the generation of cellular products for human and veterinarian uses. Persistence in our research programs has permitted ACT to be multi-faceted with several platforms for generating cellular therapies. We believe our steady, steadfast resolve to develop multiple sources of cells for transplantation will pay off in the long run, both in terms of product pipeline and controlling patent positions.a

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit [ http://www.advancedcell.com ].

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words awill,a abelieves,a aplans,a aanticipates,a aexpects,a aestimates,a and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the companya�s periodic reports, including the report on Form 10-QSB for the quarter ended September 30, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the companya�s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.Forward-looking statements are based on the beliefs, opinions, and expectations of the companya�s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.


Publication Contributing Sources